Critical

Specific Listing for Hexahydrocannabinol, A Currently Controlled Schedule I Substance

Detected July 30, 2026 · in Pharmaceutical Manufacturing (FDA/DEA)

DEA establishes a specific listing and drug code for hexahydrocannabinol (HHC) as a Schedule I controlled substance, effective immediately upon publication.

Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on July 30, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Critical. All manufacturers, distributors, researchers, and handlers of hexahydrocannabinol (HHC) subject to DEA jurisdiction. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Immediately upon publication (May 4, 2026).. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.

What changed

HHC now has a specific DEA Controlled Substances Code Number (drug code) and is explicitly listed as a Schedule I substance, clarifying its regulatory status.

Who it affects

All manufacturers, distributors, researchers, and handlers of hexahydrocannabinol (HHC) subject to DEA jurisdiction.

What you must do

Ensure all activities involving HHC comply with Schedule I requirements: register with DEA, obtain quotas, and follow security and recordkeeping rules.

Deadline

Immediately upon publication (May 4, 2026).

Source: https://www.federalregister.gov/documents/2026/05/04/2026-08595/specific-listing-for-hexahydrocannabinol-a-currently-controlled-schedule-i-substance

Never miss a change like this again

Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.

Start your free trial

Related changes in Pharmaceutical Manufacturing (FDA/DEA)